Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
Primary Care
Is there any reason to stop mesalamine in a patient with UC undergoing breast/regional nodal radiation?
Answer from: Radiation Oncologist at Community Practice
I have run into this situation a few times and have not stopped mesalamine during breast radiation. Have not noticed any issues.
Sign in or Register to read more
11392
Related Questions
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
In what circumstances would you offer axillary re-irradiation after salvage axillary dissection?
Would you consider omitting adjuvant radiation in a very elderly patient with a small triple negative breast cancer?
How would you manage an isolated nodal recurrence of breast cancer in a patient with a prior history of mantle-field radiation?
Given the 10-year outcomes of UK FAST-Forward presented at ESTRO, how have you expanded the use of ultra-hypofractionation in your practice?
What is the maximum dose that you would give to residual unresectable gross disease in the axilla in the setting of recurrent breast cancer s/p ALND?
Is it appropriate to use bolus with hypofractionated PMRT?
Is there additional concern for late cardiac toxicity when using ultrahypofractionated breast radiation protocols, given that the BED to the heart is higher?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?